Literature DB >> 11732859

Association of T102C polymorphism of the 5-HT2A receptor gene with psychiatric status in fibromyalgia syndrome.

S Gürsoy1, E Erdal, H Herken, E Madenci, B Alaşehirli.   

Abstract

Serotonin (5-HT) is a key neurotransmitter in the central nervous system. It is suggested that serotonergic dysfunction may be involved in the pathophysiology of fibromyalgia syndrome (FS). In this study, we aimed to investigate T102C polymorphism of the 5-HT2A receptor gene in FS. Fifty-eight patients with FS and 58 unrelated healthy volunteer controls were included in the study. In both groups, the C/C, C/T, and T/T genotypes of the 5-HT gene were represented in 31% (22.4% in controls), 50% (53.4%), and 19% (24.1%), respectively. The 5-HT2A receptor gene polymorphism results were not significantly different between patients and controls (chi squared test, P>0.05). There was a significant correlation between patients with the T/T genotype and the subgroup according to the SCL-90-R test, (analysis of variance, P<0.05). We also saw that patients with the T/T genotype had the lowest pain threshold. CONCLUSION. T102C polymorphism of the 5-HT2A receptor gene is not associated with the etiology of FS. Our results also indicate that the T/T genotype may be responsible for psychiatric symptoms of FS.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11732859     DOI: 10.1007/s002960100130

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  25 in total

1.  [Etiology and pathophysiology of fibromyalgia syndrome and chronic widespread pain].

Authors:  C Sommer; W Häuser; K Gerhold; P Joraschky; F Petzke; T Tölle; N Uçeyler; A Winkelmann; K Thieme
Journal:  Schmerz       Date:  2008-06       Impact factor: 1.107

Review 2.  Candidate gene studies of fibromyalgia: a systematic review and meta-analysis.

Authors:  Young Ho Lee; Sung Jae Choi; Jong Dae Ji; Gwan Gyu Song
Journal:  Rheumatol Int       Date:  2010-12-01       Impact factor: 2.631

Review 3.  Fibromyalgia: present to future.

Authors:  Robert Bennett
Journal:  Curr Rheumatol Rep       Date:  2005-10       Impact factor: 4.592

Review 4.  The phenotypic and genetic signatures of common musculoskeletal pain conditions.

Authors:  Luda Diatchenko; Roger B Fillingim; Shad B Smith; William Maixner
Journal:  Nat Rev Rheumatol       Date:  2013-04-02       Impact factor: 20.543

Review 5.  Sleep disorders and fibromyalgia.

Authors:  Suely Roizenblatt; Nilton Salles Rosa Neto; Sergio Tufik
Journal:  Curr Pain Headache Rep       Date:  2011-10

6.  Genetic variation in neuroendocrine genes associates with somatic symptoms in the general population: results from the EPIFUND study.

Authors:  Kate L Holliday; Gary J Macfarlane; Barbara I Nicholl; Francis Creed; Wendy Thomson; John McBeth
Journal:  J Psychosom Res       Date:  2010-05       Impact factor: 3.006

7.  The association between fibromyalgia and polymorphism of monoamine oxidase A and interleukin-4.

Authors:  Shan-Yu Su; Jonathan Jiunn-Horng Chen; Chien-Chen Lai; Chun-Ming Chen; Fuu-Jen Tsai
Journal:  Clin Rheumatol       Date:  2006-03-18       Impact factor: 2.980

8.  Polymorphisms of the serotonin-2A receptor and catechol-O-methyltransferase genes: a study on fibromyalgia susceptibility.

Authors:  Berna Tander; Sezgin Gunes; Omer Boke; Gamze Alayli; Nurten Kara; Hasan Bagci; Ferhan Canturk
Journal:  Rheumatol Int       Date:  2008-01-15       Impact factor: 2.631

Review 9.  Fibromyalgia: A Critical and Comprehensive Review.

Authors:  Andrea T Borchers; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-10       Impact factor: 8.667

10.  Missense mutations in the MEFV gene are associated with fibromyalgia syndrome and correlate with elevated IL-1beta plasma levels.

Authors:  Jinong Feng; Zhifang Zhang; Wenyan Li; Xiaoming Shen; Wenjia Song; Chunmei Yang; Frances Chang; Jeffrey Longmate; Claudia Marek; R Paul St Amand; Theodore G Krontiris; John E Shively; Steve S Sommer
Journal:  PLoS One       Date:  2009-12-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.